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ABSTRACT
Objective To examine the infl uence of post-symptom-
onset pregnancy on disease outcome in women with 
infl ammatory polyarthritis (IP).
Methods A total of 631 women, aged <48 years at 
symptom onset, were registered with the Norfolk Arthritis 
Register (NOAR) between 1990 and 2004. Functional 
disability was assessed using the Stanford Health 
Assessment Questionnaire (HAQ). Blood was tested 
for rheumatoid factor (RF) and anti-cyclic citrullinated 
peptide antibody (ACPA). The date and outcome of all 
pregnancies were reported during a median follow-up 
of 7 years. Linear random effects models were used to 
examine HAQ score over time, by pregnancy status. 
Results were then stratifi ed for RF and ACPA status.
Results In all, 72 women had a post-onset pregnancy 
(Po-P) including 45 women who were pregnant at 
a follow-up assessment. Pregnancy was generally 
associated with lower HAQ scores over time than non-
pregnancy. The 10 ACPA-positive women who had a Po-P 
had signifi cantly worse subsequent HAQ scores.
Conclusion Overall, Po-P is associated with lower 
HAQ scores, compared to no Po-P. This may refl ect a 
benefi cial effect of pregnancy on disease outcome, or 
that predominantly women with milder disease become 
pregnant. In women with the worst predicted outcome 
(APCA positive), Po-P is associated with a worse 
outcome than no pregnancy.
Hench ﬁ rst reported the association between preg-
nancy and an improvement in symptoms of inﬂ am-
matory polyarthritis (IP) and rheumatoid arthritis 
(RA) in 1935.1 Since then a number of studies have 
replicated the observation2 3 and results from the 
Physical Activity in Rheumatoid Arthritis (PARA) 
study suggest that rheumatoid factor (RF) and 
anti-cyclic citrullinated peptide antibody (ACPA)-
negative women are more likely to show an 
improvement of RA symptoms during pregnancy 
than autoantibody-positive women.4
The long-term effects of pregnancy on RA out-
come have been less studied. A retrospective study 
of 200 Finnish women patients with RA, half of 
whom had a post-onset pregnancy (Po-P), reported 
no signiﬁ cant effect of Po-P on prognosis.5 A pro-
spectively followed inception cohort of 132 Dutch 
women with RA, 24 of whom had a Po-P reported 
no signiﬁ cant effect of Po-P on cross-sectional dis-
ease outcome at 12 years.6 We sought to contribute 
to this area by investigating the inﬂ uence of Po-P 
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on subsequent disease outcome in our cohort of 
women with recent onset IP. We also explored the 
impact of autoantibody status.
PATIENTS AND METHODS
Patients
The cohort comprised consecutive women aged 
<48 years at symptom onset (our oldest recorded 
age at pregnancy), who were registered with the 
Norfolk Arthritis Register (NOAR) between January 
1990 and December 2004. NOAR is a primary 
care-based inception cohort of patients with recent 
onset IP.7 Patients underwent a standardised assess-
ment by a research nurse at baseline and years 1, 2, 
3, 5, 7, 10 and 15.
Data collection
At each assessment the patient completed the 
British version of the Stanford Health Assessment 
Questionnaire (HAQ).8 Blood samples taken at 
baseline and during follow-up were tested for RF 
(latex method; positive result was a titre ≥1:40) 
and ACPA (Axis-Shield DIASTAT kit, Axis-Shield, 
Cambridge, UK; positive: >5 U/ml). At each assess-
ment the patient was asked about the dates and 
outcome of any pregnancies. Pregnancies resulting 
in multiple births were counted as one live birth. 
Women were regarded as ‘pregnant at assessment’ 
if their assessment took place less than 40 weeks 
before the date of delivery.
Statistical analysis
Independent samples t tests, Wilcoxon/Mann–
Whitney tests, χ2 tests and logistic regression, as 
appropriate to the data characteristics, were used 
to test for differences in the baseline characteristics 
of women with and without a Po-P. Linear random 
effects (LRE) models were used to compare HAQ 
score over time, by pregnancy status (see supple-
mentary material). We deﬁ ned pregnancy status 
as a non-time variable constant based on whether 
patients had a Po-P or not at any time during follow-
up, and then as a time variable factor (not yet had a 
Po-P vs had a Po-P) which allowed for the timing of 
pregnancies and comparison of the HAQ scores of 
women who had a pregnancy, with their estimated 
trajectory had they not had a pregnancy. For the 
LRE models, patients were classiﬁ ed as ‘positive’ 
for RF or ACPA, if they had a positive test result at 
any time post onset. Adjustment was made for age 
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at symptom onset and symptom duration at baseline in all of 
the LRE models. All analysis was carried out using STATA V.10 
(StataCorp, College Station, Texas, USA).
RESULTS
Baseline characteristics
A total of 631 women satisﬁ ed the entry criteria for the study. 
Their baseline characteristics are presented in table 1. The 
median (IQR) follow-up time was 6.9 years (4.1–12.2) and the 
total follow-up time was 4733 person-years. In all, 72 (11.4%) 
women had at least 1 pregnancy during follow-up, and 45 
women were pregnant at the time of an assessment.
Women who had a Po-P were younger at symptom onset, less 
likely to be positive for ACPA, or meet the American College 
of Rheumatology (ACR) criteria for RA, more likely to be tak-
ing the contraceptive pill at baseline, and had fewer previous 
pregnancies than women who did not have a Po-P (table 1). 
There were no signiﬁ cant baseline differences in disease activity 
between women who did and did not have a Po-P.
Baseline associations with Po-P
Younger age at symptom onset was a signiﬁ cant predictor of Po-P 
(table 1). Neither baseline HAQ nor 28-joint Disease Activity 
Score (DAS28) results were signiﬁ cantly associated with Po-P.
Po-P and HAQ score
The estimated changes in HAQ score by Po-P status (non-time 
variable) are shown in table 2. For clarity, we have only pre-
sented results at years 1, 5, 10 and 15 of follow-up. From year 
5 onwards, women with a Po-P had signiﬁ cantly lower HAQ 
scores than women who did not have a Po-P.
Time variable pregnancy status and HAQ score
When pregnancy was treated as a time variable factor, women 
who had a pregnancy during follow-up had lower HAQ scores 
over time than they would have done had they not had a preg-
nancy by that time (−0.16; 95% CI −0.25 to −0.06), adjusting 
for age at symptom onset, symptom duration at baseline and 
number of previous live births.
Table 1 Baseline characteristics by post-onset pregnancy and baseline associations with likelihood of post-onset pregnancy (adjusted for age at 
symptom onset)
Cohort characteristics at baseline
Women who had a  
post-onset pregnancy 
(N = 72)
Women who did not have 
a post-onset pregnancy 
(N = 559) p Value
OR* of post-onset 
pregnancy (95% CI) 
(reference)
Age at IP onset, years: median (IQR) 27.8 (23.1–30.4); n = 72  39.0 (33.1–44.0); n = 559 <0.001† 0.83 (0.80 to 0.87)‡ (per year increase)
Number of live births by baseline: n/N (%) <0.001† 0.79 (0.59 to 1.06) (per live birth)
 0 33/72 (45.8) 106/559 (19.0)
 1 23/72 (31.9)  84/559 (15.0)
 2 13/72 (18.1) 229/559 (41.0)
 3  1/72 (1.4) 103/559 (18.4)
 4  2/72 (2.8)  28/559 (5.0)
 5 –   9/559 (1.6)
Taking contraceptive pill at baseline: n/N (%) 32/72 (44.4) 102/559 (18.3) <0.001† 1.58 (0.88 to 2.85) (vs not taking)
Symptom duration, months: median (IQR)  7.5 (3.5–12.1); n = 72   6.9 (3.2–14.8); n = 559 0.94 0.99 (0.97 to 1.00) (per month increase)
Met ACR (1987) criteria for RA16: n/N (%) 17/72 (23.6) 199/559 (35.6) 0.04† 0.59 (0.31 to 1.13) (vs did not meet)
Positive for RF: n/N (%) 12/61 (19.7) 122/486 (25.1) 0.35 1.08 (0.51 to 2.29) (vs negative for RF)
Ever positive for RF during follow-up: n/N (%) 19/70 (27) 215/539 (40) – –
Positive for ACPA: n (%)  6/56 (10.7) 118/463 (25.5) 0.01† 0.41 (0.16 to 1.07) (vs negative for ACPA)
Ever positive for ACPA during follow-up: n/N (%) 10/64 (16) 135/507 (27) – –
CRP concentration, mg/litre: mean (SD) 10.0 (17.8); n = 55  10.8 (21.4); n = 447 0.80 0.99 (0.98 to 1.01) (per mg/litre increase)
Swollen and tender joint count (51 joints): median 
(IQR)
 1 (0–4); n = 72   2 (0–6); n = 559 0.36 0.98 (0.93 to 1.03) (per joint increase)
DAS28: mean (SD)  3.5 (1.3); n = 55   3.6 (1.3); n = 447 0.60 0.96 (0.75 to 1.22) (per increase of 1.0)
HAQ score: median (IQR)  0.63 (0.19–1.0); n = 72   0.75 (0.25–1.38); n = 551 0.10 0.66 (0.43 to 1.01) (per increase of 1.0)
*OR, association with likelihood of having a post-onset pregnancy, compared to (reference).
†Signifi cant difference (unadjusted).
‡Signifi cant association with likelihood of post-onset pregnancy.
ACPA, anti-cyclic citrullinated peptide antibody; ACR, American College of Rheumatology; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment 
Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.
Table 2 Change in HAQ score from baseline at years 1, 5, 10 and 15 of follow-up by post-onset pregnancy status, and difference between women 
with and without a post-onset pregnancy, adjusted for age at symptom onset and symptom duration at baseline
Follow-up anniversary
Post-onset pregnancy No post-onset pregnancy
Difference: pregnancy 
versus no pregnancy 
(95% CI)n
Change in HAQ score 
from baseline (95% CI) n
Change in HAQ score from 
baseline (95% CI)
1 70 −0.25 (−0.44 to −0.05)* 542 −0.08 (−0.13 to −0.03)* −0.17 (−0.36 to 0.03)
5 67 −0.23 (−0.43 to −0.03)* 441 −0.01 (−0.06 to 0.05) −0.22 (−0.42 to −0.02)†
10 27 −0.16 (−0.40 to 0.07) 179 0.10 (0.03 to 0.18)* −0.27 (−0.51 to −0.03)†
15 22 −0.11 (−0.35 to 0.14) 114 0.21 (0.12 to 0.29)* −0.31 (−0.57 to −0.06)†
*Signifi cant change in HAQ score from baseline.
†Signifi cant difference in change in HAQ score from baseline, by post-onset pregnancy.
HAQ, Health Assessment Questionnaire.
19_annrheumdis128769.indd   1835 8/25/2010   5:07:26 PM
Concise report
Ann Rheum Dis 2010;69:1834–1837. doi:10.1136/ard.2010.1287691836
Pregnancy at assessment and HAQ score
Women who were pregnant at assessment had signiﬁ cantly 
lower HAQ scores over time (−0.18; 95% CI −0.33 to −0.03) 
than estimated had they not been pregnant, adjusting for age at 
symptom onset, symptom duration at baseline and number of 
previous live births.
Change in HAQ score and Po-P by autoantibody status
RF-negative and ACPA-negative women who had a Po-P had 
signiﬁ cantly lower HAQ scores over time than RF-negative 
and ACPA-negative women who had no Po-Ps. The 10 ACPA-
positive women who had a Po-P had signiﬁ cantly higher HAQ 
scores than ACPA-positive women who had no Po-P (table 
3) (see supplementary material for the HAQ scores for these 
women). We repeated the original LRE model, with time 
variable pregnancy status, for each autoantibody subgroup 
(table 3). Similar results were found using both statistical 
techniques.
DISCUSSION
In our investigation we found that women who had at least one 
Po-P had lower HAQ scores over the entire follow-up period 
and following pregnancy than women who did not have a Po-P. 
These results do not support previous studies of long-term dis-
ease outcome following pregnancy;5 6 however there are many 
methodological differences. The relationship between Po-P sta-
tus and HAQ score varied with RF and ACPA status. Conﬁ rming 
the ﬁ ndings of previous studies,1–3 9 we found that women who 
were pregnant at the time of an assessment had signiﬁ cantly 
lower estimated HAQ scores than they would have done had 
they not been pregnant.
Women who had a Po-P were younger at symptom onset 
and less likely to be ACPA positive or meet the ACR crite-
ria for RA than those who had no pregnancy. This may be 
because patients with more severe disease are less likely to 
want to increase the size of their family. Thus the women 
who had a pregnancy may have had better disease outcome 
even if they had had no further pregnancies. However, once 
adjusted for age at symptom onset there were no signiﬁ cant 
differences between the two groups. The difference in HAQ 
scores were non-signiﬁ cant until the ﬁ fth anniversary, by 
which time 90% of the ‘had Po-P’ group had been pregnant. 
This suggests that the two groups of women were not dif-
ferent before pregnancy. In either case, we have shown that, 
in general, pregnancy was not associated with a detrimental 
effect on disease outcome.
Our results support previous ﬁ ndings that patients with sero-
negative RA are more likely to experience amelioration during 
pregnancy than patients who are seropositive.4 Among the 
ACPA-positive women in our cohort, pregnancy was associated 
with higher HAQ scores than no pregnancy, although numbers 
are small. It is possible that pregnancy and subsequent childcare 
placed an added strain on those with an underlying poor prog-
nosis10 leading ultimately to a worse outcome. Further studies in 
ACPA-positive women are needed to determine the inﬂ uence of 
Po-P in this subgroup.
This is the largest prospective study to investigate the 
impact of Po-P in a cohort of patients with recent onset IP. The 
strengths and weaknesses of the recruitment of patients with IP 
from primary care in NOAR have been discussed elsewhere.7 
One weakness of the current study is that we have not con-
sidered treatment effects. Many women stop taking treatment 
while they are pregnant, breast feeding or trying to conceive9 
11 which, if anything, would to lead to a worse outcome, hence 
more intensive treatment is unlikely to explain our ﬁ ndings.
The ‘changing maternal ‘self’ hypothesis’ describes how, dur-
ing pregnancy, fetal cells in the mother’s blood stream (microchi-
merism) cause the mother’s immune system to reidentify ‘self’, 
resulting in an amelioration of RA symptoms. Microchimerism 
can persist for decades postpartum, thus resulting in a long-term 
improvement in disease.12 The level of fetal DNA in the moth-
er’s blood has been found to correlate with disease  activity.13 
However, a recent study found that microchimerism of 
RA-associated human leucocyte antigen (HLA) alleles is found 
more frequently in women with RA than in non-RA controls.14 
Microchimerism may have either a beneﬁ cial (by contributing to 
tissue repair) or adverse (via fetal cells acting as effector cells or 
the targets of immune attack) effect on disease severity among 
patients with RA.15 It is possible that in the presence of ACPA, 
fetal cells have the opposite effect than in situations when ACPA 
is absent, or at low levels. Alternatively, the temporary amelio-
ration of rheumatological symptoms during pregnancy may lead 
to a reduction in cumulative disease burden, thus producing the 
effect seen here.
Thus, in general, patients with IP who become pregnant after 
symptom onset have less functional disability than patients 
with IP who do not become pregnant after symptom onset. 
Seronegative women with IP should not be discouraged from 
becoming pregnant.
Table 3 Infl uence of post-onset pregnancy status and cumulative autoantibody status on change in HAQ score over time, adjusted for age at 
symptom onset, symptom duration at baseline and number of previous live births
RF status ACPA status
 Negative Positive Negative Positive
Post-onset pregnancy
 No Ref.   0.10 Ref. 0.17
 Yes −0.23   0.05 −0.28 0.54
Difference in change in HAQ score by post-onset 
pregnancy status (95% CI)
−0.23 (−0.34 to −0.12)* −0.05 (−0.22 to 0.11) −0.28 (−0.39 to −0.18)* 0.37 (0.14 to 0.59)*
Results from stratifi ed LRE models
Difference in change in HAQ score by post-onset 
pregnancy status (95% CI)
−0.16 (−0.28 to −0.05)* −0.08 (−0.26 to 0.10) −0.23 (−0.34 to −0.12)* 0.31 (0.05 to 0.56)*
In the top half of the table, autoantibody-negative women without a post-onset pregnancy are the reference group (Ref). Values represent difference in HAQ score from the reference 
group.
*Signifi cant difference between HAQ scores of women who had a pregnancy and women who had not.
ACPA, anti-cyclic citrullinated peptide antibody; HAQ, Health Assessment Questionnaire; LRE, linear random effect; RF, rheumatoid factor.
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